8 results about "Undifferentiated cell" patented technology

The invention relates to the technical field of biology, and particularly discloses a method for preparing mesenchymal stem cells by utilizing differential settlement sorting cell balls. According to the method, the differential sedimentation method is adopted, the diameters of the embryoid cell balls are sorted according to the size, the diameter uniformity of the embryoid cell balls is remarkably improved, and then the uniformity and stability of subsequent differentiation products are improved. According to the method provided by the invention, reagent components are clear, facility requirements are simple, differentiation efficiency is high, the iMSC conforming to the identification standard can be obtained by rapidly differentiating for 20 days, the obtained iMSC is good in uniformity and less in undifferentiated cell residue, and the method has potential value in clinical transformation application.

The invention relates to a method for obtaining a dental prosthesis comprising a crown and a root. The method comprises at least one step of guiding undifferentiated cells or keratinocytes and at least one step of three-dimensional printing, preferably 3D bioprinting of the dental prosthesis. Furthermore, the invention relates to a dental prosthesis obtained using said method, as well as to bio-inks suitable for three-dimensional printing (3D), preferably for 3D bioprinting.

The invention provides a C2BBe1 intestinal cell reprogramming method and system, and aims to solve the technical problems of low reprogramming efficiency, unstable reprogramming result, difficulty in truly simulating in-vivo real conditions and difficulty in driving intestinal epithelial cell physiological morphology and differentiation maintenance in current intestinal tissue modeling. An in-vivo intestinal canal model and an in-vitro gas-liquid exchange interface model are constructed, real in-vivo conditions can be simulated, a crypt-villus topological structure can be reconstructed spontaneously, and spatial heterogeneity and cell lineage distribution of intestinal epithelium can be simulated truly. After specific mechanical stimulation characteristic verification of the intestinal canal at different development stages is carried out, a verification result is obtained, and actual in-vitro inoculation is carried out on the basis of the verification result. And finally undifferentiated cells can be directly reprogrammed, so that the dependence on pluripotent stem cells and a complex induction process in a traditional method is avoided, and the reprogramming efficiency and stability are remarkably improved.

Provided is a technique for producing an organoid that is larger in size and more functionally excellent than conventional organoids. The present invention employs a method for producing an organoid, the method comprising: a step (A1) for culturing an organoid, in which an organoid produced from undifferentiated cells, mesenchymal cells, and vascular cells that differentiate into a first organ is brought into a secretion factor secreted from a second organ; and a step (A2) for culturing the organoid cultured in the step (A1). In the step (A1) and the step (A2), the dissolved oxygen partial pressure of a medium in contact with the organoid is 20% or less. The dissolved oxygen partial pressure of the medium in contact with the organoid in the step (A1) is lower than the dissolved oxygen partial pressure of the medium in contact with the organoid in the step (A2).

The invention relates to a process for the preparation of an extract obtained from undifferentiated cell suspension cultures of clary sage, to the extract obtained by this process, to the use of this extract as an active ingredient in the prevention and / or treatment of inflammation or microbial infections, to a pharmaceutical composition comprising said extract, to a sanitizing composition comprising said extract, to the use of said sanitizing composition for sanitizing a surface or increasing the surface's resistance to microbe transmission, to the cosmetic use of said extract as an anti-aging active ingredient and to a cosmetic composition comprising said extract

The present application relates to the field of biological medicine, and particularly relates to a composition for reducing stem cell transplantation rejection and application. The composition can reduce the proliferation and activation ability of T cells in combination with peptide I, peptide II and compound extract group. By combining with specific receptors on the surface of T cells, the calcium modulator phosphatase / NFAT pathway is blocked, the secretion of IFN-gamma and IL-2 and other cytokines is reduced, so that the proliferation and activation of T cells are inhibited. At the same time, the composition can induce the production of regulatory T cells and suppressor T cells, up-regulate the expression of TGF-beta and IDO, promote the differentiation of undifferentiated T cells into Treg cells, and enhance the inhibitory function of Treg cells; can also regulate Th1 / Th2 cytokine secretion, reduce Th1 type cytokine secretion, increase Th2 type cytokine secretion, and induce immune tolerance of the body.

The invention relates to methods and devices for size-based separation of undifferentiated cells from a population of cells using curvilinear microfluidic channels. The curvilinear microfluidic channels may be a spiral microfluidic channels. The differentiated cells are spinal cord progenitor cells (SCPCs), neural progenitor cells (NPCs) and / or cells differentiated therefrom. The method may comprise flowing an input population of cells through first and second sequentially connected and fluidically communicating curvilinear microfluidic channels, wherein the first channel is coupled to an inlet and the second channel is coupled to one or more outlets, wherein the first curvilinear microfluidic channel has a smaller cross-sectional area than the second curvilinear microfluidic channel.

The invention relates to the field of biological medicine, in particular to a composition for reducing stem cell transplantation rejection and application. The composition is combined with the peptide I, the peptide II and the compound extract group, so that the proliferation and activation capacities of T cells can be reduced. By combining with a specific receptor on the surface of a T cell, a calmodulin / NFAT pathway is blocked, and secretion of cell factors such as IFN-gamma and IL-2 is reduced, so that proliferation and activation of the T cell are inhibited. Meanwhile, the composition can induce generation of regulatory T cells and inhibitory T cells, promote differentiation of undifferentiated T cells to Treg cells by up-regulating expression of TGF-beta and IDO, and enhance the inhibition function of the Treg cells; th1 / Th2 cytokine secretion can also be regulated, so that Th1 type cytokine secretion is reduced, Th2 type cytokine secretion is increased, and body immune tolerance is induced.